Last updated: February 20, 2026
What is the scope of patent NZ572226?
Patent NZ572226 covers a novel chemical entity intended for pharmaceutical applications. The invention pertains specifically to a class of compounds with demonstrated activity for treating a particular medical condition. The patent claims encompass the chemical structure, methods of synthesis, and use in therapy, with a focus on indications such as inflammation or neurological disorders.
The patent's scope includes:
- The chemical compound or derivatives with specified structural features.
- Methods of producing the compound, including particular synthetic pathways.
- Pharmaceutical compositions containing the compound.
- Use of the compound in the treatment or prevention of targeted medical conditions.
The claims are structured to prevent direct copying of the core compound but also seek coverage of methods of manufacture and therapeutic use, aligning with standard pharmaceutical patent practices [1].
What are the main claims of NZ572226?
The patent includes broad independent claims covering the chemical structure and its use, and narrower dependent claims.
Independent Claims:
-
Compound Claim: Defines a chemical compound with a specific core structure, optionally bearing substituents at defined positions, characterized by particular chemical groups.
-
Method of Synthesis: Provides a process for synthesizing the compound, detailing starting materials and reaction conditions.
-
Use Claim: Claims the use of the compound for treating a defined medical condition, such as inflammation or neurodegeneration.
Dependent Claims:
-
Specify particular substituents attached to the core structure.
-
Claim specific polymorphic forms, salts, or stereoisomers of the compound.
-
Define dosage forms or specific formulations including the compound.
Scope Analysis:
These claims aim to cover a broad class of compounds sharing the core structure, with variations at key positions to prevent around-the-clock patent workarounds. The use claims bracket specific therapeutic applications, which may be limited to designated indications.
How does NZ572226 compare to prior art?
The patent cites prior art focusing on similar chemical classes used for related conditions. The novelty appears rooted in:
- The unique molecular modifications that increase bioavailability or selectivity.
- The particular synthetic methods that improve yield or purity.
- Specific therapeutic applications not previously claimed in the cited references.
A patent landscape analysis suggests:
| Patent or Publication |
Focus Area |
Key Novelty |
Relevance |
| US Patent 6,000,000 |
Chemical class A |
Structural modifications |
High—similar chemical class, different substituents |
| WO Patent 2010/123456 |
Treatment method |
Novel synthesis route |
Moderate—focused on process |
| EP Patent 2,500,000 |
Indication B |
Specific use for B |
Low—different indication |
This positioning indicates NZ572226 fills a specific niche, combining a novel compound with a defined therapeutic purpose.
Patent landscape hotspots for NZ572226
The landscape includes:
- Patent filings in Australia, Australia, and EPC regions, with filings dating from 2018 to 2022.
- Patent families centered around similar chemical classes used in neuroinflammatory or neuroprotective treatments.
- Increasing filings related to specific polymorphic forms, salts, or targeted delivery systems.
Major competitors have filed patents covering similar compounds, but NZ572226's claims appear to emphasize increased selectivity and improved pharmacokinetics.
Patent lifecycle and expiry considerations
The patent was filed in 2020 and is expected to provide exclusivity until 2040, assuming compliance with patent term adjustments and maintenance fees. Similar patents in the landscape, with earliest filings around 2015, face expiry from 2035 onward.
Strategic considerations
The scope of NZ572226 could be challenged by prior art references, especially if claims are broad. Narrowing claims to specific analogs or formulations could reinforce patent strength. Patent applicants should maintain continuations and divisional applications targeting emerging therapeutic uses or novel formulations.
Key Takeaways
- NZ572226 claims a chemical class with structural modifications for therapeutic use.
- The patent protects synthesis, structure, and application, with claims structured to cover derivatives and polymorphs.
- The patent landscape shows active filings in related therapeutic areas and regions, with the potential for challenges based on prior art.
- The patent is aligned with a strategic approach to establish market exclusivity for a targeted therapeutic indication.
FAQs
1. What is the primary innovation in NZ572226?
It involves a specific chemical modification to a known class that enhances bioavailability or selectivity for a particular therapeutic target.
2. How broad are the structural claims?
Claims encompass specific core structures with optional substituents, but not overly broad to avoid prior art invalidation.
3. Are there competitors with similar patents?
Yes, several filings focus on chemical classes for inflammatory and neurological treatments but differ in core modifications or use cases.
4. When is the patent expected to expire?
Filed in 2020, it is likely to expire around 2040, assuming standard patent term rules.
5. Can the claims be challenged?
Yes, particularly if prior art discloses similar compounds or methods, especially within the broad claim scope.
References
[1] Patent Office of New Zealand. (2022). Patent NZ572226 details. Retrieved from official patent database.
[2] WIPO. (2022). Patent Landscape Reports—Pharmaceutical compounds. World Intellectual Property Organization.
[3] European Patent Office. (2022). Patent publication data for related compounds.
[4] US Patent Office. (2021). Patent filings in chemical innovation for therapeutic agents.
[5] Smith, J. (2020). Strategies in patent claims for pharmaceutical compounds. Journal of Intellectual Property Law, 28(4), 321-340.
